Roche Gains FDA Priority Review Acceptance for Giredestrant NDA in Early-Stage ER-Positive Breast Cancer

With a PDUFA date of 30 November 2026, Roche's manufacturing and regulatory affairs teams now face a defined window to complete commercial-scale readiness, labeling submissions, and GMP compliance documentation for giredestrant, an oral selective estrogen receptor degrader (SERD) that, if approved, would be the first new adjuvant endocrine therapy in over 20 years.

The FDA accepted Roche's New Drug Application under Priority Review for giredestrant as an adjuvant treatment for adults with estrogen receptor (ER)-positive, HER2-negative, stage I, II, and III breast cancer. The acceptance is grounded in data from the phase III lidERA Breast Cancer study (NCT04961996), which demonstrated a 30% reduction in the risk of invasive disease recurrence or death compared with standard-of-care endocrine therapy (hazard ratio 0.70; 95% CI 0.57–0.87; p=0.0014). At three years, 92.4% of patients in the giredestrant arm remained alive and free of invasive disease versus 89.6% in the standard-of-care arm.

The tolerability profile carries direct implications for adherence modeling and post-approval commitments. Treatment discontinuation with giredestrant was 5.3%, compared with 8.2% for standard-of-care endocrine therapy, a differential that will likely inform labeling language and risk management frameworks under 21 CFR Part 314. Overall survival data were immature at the time of analysis; follow-up continues to the next pre-specified assessment.

For regulatory affairs leads, the parallel NDA track is relevant context. The FDA separately accepted a second giredestrant NDA, this one in combination with everolimus for ESR1-mutated, ER-positive advanced breast cancer based on the evERA study, with a decision expected in December 2026. Two concurrent review cycles for the same active moiety will require coordinated labeling strategy and, where applicable, aligned CMC documentation across both submissions.

The adjuvant indication targets a substantial patient population: more than 90% of ER-positive breast cancer cases are diagnosed at early stage (I–III), and up to one-third of patients experience recurrence on or after current adjuvant endocrine therapy. Giredestrant's iDFS benefit was consistent across all clinically relevant subgroups, which will bear on the scope of the approved indication and any post-marketing study commitments the agency may attach.

Process validation timelines and commercial batch documentation will need to align with the November 2026 action date if Roche intends to launch without delay following a potential approval.

Source: Roche via GlobeNewswire, 2 June 2026.